US pharma firm Acadia buys Polish drug rights in EUR 102-mln deal
US pharmaceutical company Acadia has purchased the exclusive rights to the development of a new neuropsychiatric drug from the Polish company Adamed in a deal worth above PLN 470 million (EUR 102 million).
Adamed has carried out the transaction at an early stage of research, the Puls Biznesu economic newspaper reported.
"We are granting an exclusive licence for the further development of the drug," the newspaper was told by Bartlomiej Zerek, Innovation Department director at Adamed.
Zerek added that his company would retain exclusive rights for the sale of the new drug on Polish and other European markets.
Nasdaq-listed Acadia specialises in neuropsychiatric drugs.